XBRANEXbrane Biopharma ABXBRANE info
$0.02info-5.64%24h
Global rank
Market cap$498.76K
Change 7d27.08%
YTD Performance-98.29%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Xbrane Biopharma AB (XBRANE) Stock Overview

    Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Ximluci, a ranibizumab biosimilar used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults. Its pre-clinical phase products include BIIB801, a biosimilar candidate for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease, and axial spondylitis; Xdivane for skin cancer, lung cancer, renal cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xtrudane for brain cancer, melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; and Xdarzane for multiple melanoma. Xbrane Biopharma AB (publ) was incorporated in 2008 and is headquartered in Solna, Sweden.

    XBRANE Stock Information

    Symbol
    XBRANE
    Address
    Retzius vAeg 8Solna, 171 65Sweden
    Founded
    -
    Trading hours
    -
    Website
    https://www.xbrane.com
    Country
    πŸ‡ΈπŸ‡ͺ Sweden
    Phone Number
    46 8 55 90 56 00

    Xbrane Biopharma AB (XBRANE) Price Chart

    -
    Value:-

    Xbrane Biopharma AB Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $0.016731155409707595
    N/A
    Market Cap
    $498.76K
    N/A
    Shares Outstanding
    29.81M
    N/A
    Employees
    92.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org